Navigation Links
AAP Initiates Public Relations Effort to Counter Bad Vaccine Publicity
Date:2/15/2008

appropriate medical attention, yet the AAP continues to dismiss these treatments."

A growing body of scientific research including a Centers for Disease Control study from 2000 indicates a link between thimerosal exposure and several specific neurological injuries including autism. For years, Shreffler and her colleagues have requested the toxins be removed from all vaccines.

"If the AAP truly wants the best possible publicity for vaccines, they can start by discouraging the use of toxic components."

For more information, visit http://www.nationalautism.org.

CONTACT: Wendy Fournier, Portsmouth, RI, 401-835-5828

Rita Shreffler, Nixa, MO, 401-632-6452


'/>"/>
SOURCE National Autism Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
2. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
3. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
4. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
5. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
6. Harbinger Research Initiates Coverage on HearAtLast
7. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
8. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
9. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
10. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
11. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Antonio, TX (PRWEB) July 22, 2014 Dr. ... Designed with existing patients and new visitors in mind, one ... clean, modern and visual layout that makes navigation very easy. ... make the experience of going to the dentist affordable, convenient ... , One helpful new feature is an appointment scheduling system ...
(Date:7/22/2014)... Indianapolis, IN (PRWEB) July 22, 2014 ... benefits advisory organization, announces that Les McPhearson, an insurance ... serve as CEO effective immediately and be based in ... Calise, said, "I am delighted that Les chose to ... is perfectly qualified to address the many challenges facing ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July 22, 2014 (HealthDay ... in the veins of the legs appear no different in ... risk of bleeding and average hospitalization bills that are three ... finds. The standard treatment for these clots -- known ... compression stockings. The other, more expensive treatment delivers medication directly ...
(Date:7/22/2014)... 22, 2014) The American Society of Hematology (ASH) ... School of Medicine, and Robert P. Hebbel, MD, of ... Ernest Beutler Lecture and Prize for their significant research ... The Ernest Beutler Lecture, named for the late Ernest ... for more than 50 years, is a two-part lectureship ...
(Date:7/22/2014)... research at the University of Utah,s John A. Moran ... of Eye Research (ISER) as the recipient of the ... Award in Retina Research., The award recognizes lifetime achievement ... contribution to the understanding of vitreoretinal diseases or disorders. ... ISER Biennial Meeting in San Francisco, where Marc will ...
Breaking Medicine News(10 mins):Health News:Dr. Dental Reveals Exciting New Website 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2
... Rostock Center for the study of Demographic Change, have ... be //soon reduced, if the trend of low participation ... ,The Rostock Center is a research institution, ... for Demographic Research and the University of Rostock. The ...
... lead in a global ,program to catalogue human mutations in ... access//. ,For a sample of the expected ... professor at the division of human genetics at the University ... a family who suffered from a heredity eye disease, which ...
... A Geography professor of Kansas State University, Doug Goodin, ... of land use and land cover //changes on human ... uses, combines remote sensing with other types of data, ... Along with other scientists he recently discussed this subject ...
... Chicago – The extended use of anabolic androgenic steroid ... // Gingival enlargement occurs when the tissues ... is a fertile environment for bacteria to grow, which ... that AAS abusers had statistically significant levels of gingival ...
... of misconception about Cannabis and its effects. It is widely ... // Such misrepresentations of the drug have resulted in making ... Karolinska Institute in Sweden have unearthed the harmful effects of ... ingredient in cannabis. It was found that the brain of ...
... medical specialist, NHS can be freed from its’ problems, ... before they are implemented. // It is amply clear ... make matters worse for the deprived and under privileged ... led to low morale among Doctors and NHS staff. ...
Cached Medicine News:Health News:Demographic Change Demand a New Life-Course for Aging Society 2Health News:Developing Countries Undertake Cataloguing of Human Mutations 2Health News:Developing Countries Undertake Cataloguing of Human Mutations 3Health News:Satellite Imagery to monitor the Social Impact Of Geographical Changes 2Health News:A connection between gingival enlargement and steroid abuse 2
(Date:7/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... has been appointed chief financial officer of the company, ... previously executive vice president and chief financial officer of ... company.  Mr. Clerkin was part of a senior team ... in its sale to Perrigo, a pharmaceutical manufacturer, in ...
(Date:7/22/2014)... LOUIS , July 22, 2014  According to ... time their children spend on digital devices. An AOA ... ages of 10 and 17 estimate they use an ... However, a separate AOA survey of parents revealed that ... an electronic device for that same amount of time. ...
(Date:7/22/2014)... LOS ANGELES , July 22, 2014  NeuroSigma, ... sciences company focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, today announced that enrollment ... external trigeminal nerve stimulation (eTNS) as adjunctive therapy for ... trial is being conducted at the Olive View-UCLA Medical ...
Breaking Medicine Technology:ConvaTec Names Nigel Clerkin Chief Financial Officer 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5
Landolt hypophysectomie instrument, spoon, bayonet-shaped, flexible....
Hardy pituitary spoon, bayonet, malleable....
... Sundt AVM Micro ... construction, non-magnetic, MRI compatible, ... coiled, high minimum closing ... of small perforating vessels ...
... Cougar is an Anterior Spinal Implant system. ... approximating that of cortical bone. The result ... requirements of anterior column support, while optimizing ... sharing design. Incorporates an anatomic design with ...
Medicine Products: